<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selected genetic disorders in which obesity is an isolated or predominant feature</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selected genetic disorders in which obesity is an isolated or predominant feature</h1>
<div class="graphic"><div class="figure"><div class="ttl">Selected genetic disorders in which obesity is an isolated or predominant feature</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup> <colgroup width="60%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Disorder (gene)</td> <td class="subtitle1">Gene</td> <td class="subtitle1">Clinical features</td> </tr> <tr class="divider_bottom"> <td><a href="https://www.omim.org/entry/614962" target="_blank">Leptin deficiency</a><br/> (various mutations interfering with synthesis or secretion of leptin)</td> <td><a href="https://www.omim.org/entry/164160" target="_blank"><em>LEP</em></a></td> <td>Severe early-onset obesity, hypometabolic rate, hyperphagia, pubertal delay, impaired glucose tolerance, hypothalamic hypogonadism, frequent infections. Leptin levels are very low or undetectable. Obesity and hyperphagia respond to replacement with exogenous recombinant <span class="nowrap_whitespace">leptin<sup>[1]</sup>.</span></td> </tr> <tr class="divider_bottom"> <td><a href="https://www.omim.org/entry/614963" target="_blank">Leptin receptor deficiency</a></td> <td><a href="https://www.omim.org/entry/601007" target="_blank"><em>LEPR</em></a></td> <td>Severe early-onset obesity, hypometabolic rate, hyperphagia, pubertal delay, hypothalamic hypogonadism. Leptin levels are high but are proportional to the degree of obesity, so they are not a useful marker for this defect. Responds to treatment with setmelanotide, a melanocortin 4 receptor agonist*, but not to exogenous <span class="nowrap_whitespace">leptin<sup>[2,3]</sup>.</span></td> </tr> <tr class="divider_bottom"> <td><a href="https://www.omim.org/entry/614962" target="_blank">Leptin dysfunction</a><br/> (biologically inactive leptin)</td> <td><em>LEP</em> (<a href="https://www.omim.org/entry/164160#0003" target="_blank"><em>LEP p.D100Y</em></a>)</td> <td>Severe early-onset obesity, hyperphagia. Leptin level are high (consistent with degree of obesity) but biologically inactive. Obesity and hyperphagia respond to treatment with exogenous recombinant <span class="nowrap_whitespace">leptin<sup>[4]</sup>.</span></td> </tr> <tr class="divider_bottom"> <td><a href="https://www.omim.org/entry/609734" target="_blank">Pro-opiomelanocortin deficiency</a></td> <td><a href="https://www.omim.org/entry/176830" target="_blank"><em>POMC</em></a></td> <td>Adrenal insufficiency (typically presenting in the neonatal period), severe early-onset obesity, hyperphagia, with pale skin and red hair in White <span class="nowrap_whitespace">individuals<sup>[5,6]</sup>.</span> Responds to treatment with setmelanotide*.</td> </tr> <tr class="divider_bottom"> <td><a href="https://www.omim.org/entry/600955" target="_blank">Proprotein convertase 1/3 deficiency</a></td> <td><a href="https://www.omim.org/entry/162150" target="_blank"><em>PCSK1</em></a>, also known as prohormone convertase 1</td> <td>Early-onset obesity, diarrhea, abnormal glucose homeostasis, hypogonadotropic hypogonadism, hypocortisolism, elevated plasma proinsulin and <span class="nowrap_whitespace">POMC<sup>[7]</sup>.</span> Responds to treatment with setmelanotide*.</td> </tr> <tr class="divider_bottom"> <td><a href="https://www.omim.org/entry/601665" target="_blank">Melanocortin 4 receptor haploinsufficiency</a></td> <td><a href="https://www.omim.org/entry/155541" target="_blank"><em>MC4R</em></a></td> <td>Early-onset moderate to severe obesity, early-onset hyperphagia, increased bone density, accelerated linear growth, severe hyperinsulinemia, mild central <span class="nowrap_whitespace">hypothyroidism<sup>[8,9]</sup>.</span></td> </tr> <tr class="divider_bottom"> <td><a href="https://www.omim.org/entry/615457" target="_blank">Melanocortin 2 receptor accessory protein 2</a></td> <td><a href="https://www.omim.org/entry/615410" target="_blank"><em>MRAP2</em></a></td> <td>Severe nonsyndromic early-onset obesity (probably very rare)<sup>[10]</sup>.</td> </tr> <tr> <td>GNAS mutations</td> <td><a href="https://www.omim.org/entry/139320" target="_blank"><em>GNAS</em></a> complex locus</td> <td>Severe early-onset obesity with or without developmental delay, short stature, brachydactyly, subcutaneous ossifications, pseudohypoparathyroidism (hypocalcemia, PTH resistance) and thyrotropin resistance (elevated TSH with normal or low <span class="nowrap_whitespace">fT4)<sup>[11]</sup></span> (eg, Albright's hereditary osteodystrophy). Obesity is likely mediated by disrupted MC4R signaling.</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>POMC: pro-opiomelanocortin; PCSK1: proprotein convertase subtilisin/kexin type 1; PTH: parathyroid hormone; GNAS: encodes the <span class="nowrap_whitespace">G-alpha<sub>s</sub></span> (stimulatory G-protein alpha subunit) protein; TSH: thyroid-stimulating hormone; fT4: free thyroxine.</p>
* Setmelanotide, a melanocortin 4 receptor agonist, is available for the treatment of obesity due to mutations in the <em>POMC</em>, <em>PCSK1</em>, or <em>LEPR</em> (leptin receptor) genes, and for patients with Bardet-Biedl <span class="nowrap_whitespace">syndrome<sup>[12]</sup>.</span> Refer to UpToDate content on genetic contributions to obesity.</div><div class="graphic_reference">References:
<ol>
<li>Farooqi IS, Matarese G, Lord GM et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic function of human congenital leptin deficiency. J Clin Invest 2002; 110:1093.</li>
<li>Clement K, Vaisse C, Lahlou N et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392:398.</li>
<li>Farooqi IS, Wangensteen T, Collins S et al. Clinical and molecular spectrum of congenital deficiency of the leptin receptor. New Engl J Med 2007; 356:237.</li>
<li>Wabitsch M, Funcke JB, Lennerz B et al. Biologically inactive leptin and early-onset extreme obesity. New Engl J Med 2015; 372:48.</li>
<li>Krude H, Biebermann H, Luck W et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998; 19:155.</li>
<li>Anisimova AS, Rubtsov PM, Akulich KA, et al. Late diagnosis of POMC deficiency and in vitro evidence of residual translation from allele with c.-11C&gt;A mutation. J Clin Endocrinol Metab 2017; 102:359.</li>
<li>Jackson RS, Creemers JW, Ohaqi S et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997; 16:303.</li>
<li>Farooqi IS, Keogh JM, Yeo GS et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. New Engl J Med 2003; 348:1085.</li>
<li>Farooqi IS. The severely obese patient – a genetic workup. Nat Clin Pract Endocrinol Metab 2006; 2:172.</li>
<li>Asai M, Ramachandrappa S, Joachim M, et al. Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesity. Science 2013; 341:275.</li>
<li>Mendes de Oliveira E, Keogh JM, Talbot F, et al. Obesity-Associated GNAS Mutations and the Melanocortin Pathway. N Engl J Med 2021; 385:1581.</li>
<li>Imcivree. US FDA approved product information: Rhythm Pharmaceuticals; June 2022. Available at: <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213793s001lbl.pdf" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213793s001lbl.pdf</a> (Accessed on June 17, 2022).</li>
</ol></div><div id="graphicVersion">Graphic 82307 Version 18.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
